No Data
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
JBM HEALTHCARE: 2024/2025 Interim Report
Hong Kong stock market anomaly | jbm healthcare (02161) rose more than 14%, hitting a new high in nearly three and a half years. Mid-term net profit increased by more than fifty percent year-on-year.
jbm healthcare (02161) rose more than 14%, reaching a high of 1.62 Hong Kong dollars, hitting a new high since June 2021. As of the time of publication, it increased by 14.89%, closing at 1.62 Hong Kong dollars, with a turnover of 9.4191 million Hong Kong dollars.
JBM (Healthcare)'s Profit Zooms 53% in Fiscal H1
jbm healthcare (02161.HK) reported a mid-term profit attributable to equity holders of 95.9 million Hong Kong dollars, an increase of approximately 53.4% year-on-year.
Grondlohui, November 19th, jbm healthcare (02161.HK) announced that the profit for the six months ended September 30, 2024, was approximately 0.399 billion Hong Kong dollars, an increase of about 22.1% compared to the same period in 2023. During the same period, the company's equity holders' share of profit was approximately 95.9 million Hong Kong dollars, an increase of about 53.4% compared to the same period in 2023. The board of directors declared an interim dividend of HK$5.50 per ordinary share for the six months ended September 30, 2024 (total amount about 45.2 million Hong Kong dollars), an increase of about 59.4% compared to HK$3.45 per ordinary share in the same period in 2023. Brand traditional chinese medicine division.
Express News | JBM (Healthcare) H1 Gross Profit HKD 205.9 Million
